|
WO2020197984A1
|
|
Methods for improving cognitive function
|
|
WO2018106849A1
|
|
Ex vivo antigen and adjuvant pulsed peripheral blood mononuclear cells as a screening platform for candidate novel vaccines and candidate antigens
|
|
US2019142831A1
|
|
Treatment of rosacea with p38 and erk kinase pathway inhibitors
|
|
US2018250512A1
|
|
Stimulation of the ventral pallidum for the treatment of epilepsy
|
|
US2016192627A1
|
|
Transgenic mice expressing human pyrin domain only protein 2
|
|
CN106794225A
|
|
Leptin related peptide of myristoylation and application thereof
|
|
WO2015123359A1
|
|
Multi-functional mucosal vaccine platform
|
|
US2016123966A1
|
|
Cyclic-di-AMP specific detection
|
|
WO2015187123A1
|
|
Dynamic decompressive craniotomy fixation devices and related methods
|
|
EP2968505A2
|
|
Compositions and methods for treating autoimmune diseases
|
|
AU2013239995A1
|
|
Blocking of cue-induced drug reinstatement
|
|
US2015030632A1
|
|
Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
|
|
EP2725997A1
|
|
Dynamic spinal plating system
|
|
WO2011088462A2
|
|
Alpha-fetoprotein 'ring and tail' peptides
|
|
US2009203624A1
|
|
Alpha-fetoprotein peptides
|
|
WO2009134489A2
|
|
Blockage of interferon-gamma for prevention of polymicrobial synergy
|
|
WO2009097259A2
|
|
Use of ibogamine congeners for treating obesity
|
|
WO2008101219A2
|
|
Compositions and methods for inhibiting or reversing fibrotic disorders
|
|
US2008039403A1
|
|
Alpha-fetoprotein peptides and uses thereof
|
|
AU2006236007A1
|
|
Cochleate Delivery Vehicles
|
